Losing momentum

The days of the momentum-based follow-on offering are gone, as a flattening of the biotech indices and dismal after-market performance have eroded investor appetite. The result is a sharp drop-off in 4Q15 follow-ons, and a market that is receptive only to companies that have delivered on key milestones.

In other words, things are back to normal...